Use of a vegf antagonist to treat angiogenic eye disorders
AssigneeRegeneron Pharmaceuticals, Inc.
InventorGeorge D. YANCOPOULOS
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
Claims16
A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;
- wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose;
- and
- wherein each tertiary dose is administered on an as-needed/pro re nata (PRN) basis, based on visual and/or anatomical outcomes as assessed by a physician or other qualified medical professional;
- wherein the VEGF antagonist is a receptor-based chimeric molecule comprising (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2;
- (2) a VEGFR2 component comprising amino acids 130-231 of SEQ ID NO:2;
- and (3) a multimerization component comprising amino acids 232-457 of SEQ ID NO:2.
(canceled)
(canceled)
-12. (canceled)
-17. (canceled)
Dependencies are inferred from the claim text.